Jaguar Animal Health (JAGX)
(Delayed Data from NSDQ)
$1.07 USD
-0.04 (-3.60%)
Updated Sep 20, 2024 03:59 PM ET
After-Market: $1.07 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth A Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
JAGX 1.07 -0.04(-3.60%)
Will JAGX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for JAGX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for JAGX
Jaguar Animal Health, Inc. (JAGX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
JAGX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for JAGX
Jaguar Health to Present September 19 at the MedInvest Biotech & Pharma Investor Conference
Jaguar Health celebrates National Service Dog Month
Jaguar Health Celebrates National Service Dog Month: With its Supportive Cancer Care Drugs, Jaguar is Dedicated to the Health and Wellbeing of People and Dogs
New Innovators with Jane King Interview with Jaguar Health CEO Lisa Conte Spotlights Company’s Near-Term Commercial & Development Milestones
Jaguar Health announces patent issued in Jordan for SBS treatment